A record of what PL Capital Analysis said publicly, with the source. Not advice.
“Maintains a 'BUY' rating on Ajanta Pharma with a target of ₹3,200, valuing it at 30x PE on September 2027 earnings. The company is expected to achieve a 13% revenue CAGR and 17%/16% EBITDA/PAT CAGR over FY25–28, indicating strong earnings visibility.”
PL Capital Analysis’s track record (trackable calls only): 19 graded calls · 95% CI 51–88%
How this call is judged
A call is judged on closing prices only: a close at its target is a hit and a close at its stop is a miss. A call that states an entry starts at the first close that reaches it; if none does in the days allowed, it was never triggered, is not graded and counts toward no hit rate.
No entry price is stated, so the call starts at the first close after it was published.
Target ₹3,200, as stated.
Window: 12 months, the default when no time frame is stated.
The target ₹3,200 was reached on a close. Hit.
The grader’s working: R4 TARGET_CALL: entered ₹2530.7 on 2025-11-27 (next trading session's close); target ₹3200 reached at close ₹3259.2 on 2026-05-14. Window 365 days — rule H3: a target call whose quote states no time frame is given 12 months, the broker convention.
How it played out
How this is worked out- Time to target
- The target was reached on a close 111 trading sessions (168 calendar days) after the entry.
- Worst close against it
- No close was ever against the call before the target was reached. Closing prices only; an intraday dip is never counted.
From the entry the grade used, on closing prices. This is a record of one past call and is not advice.